Enlivex Therapeutics Ltd.
ENLV
$1.10
$0.065.77%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.91M | 4.49M | 5.00M | 5.63M | 6.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.54M | 16.15M | 18.66M | 22.32M | 25.15M |
| Operating Income | -15.54M | -16.15M | -18.66M | -22.32M | -25.15M |
| Income Before Tax | -15.01M | -18.93M | -22.29M | -25.99M | -29.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.01 | -18.93 | -22.29 | -25.99 | -29.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.01M | -18.93M | -22.29M | -25.99M | -29.07M |
| EBIT | -15.54M | -16.15M | -18.66M | -22.32M | -25.15M |
| EBITDA | -14.99M | -15.44M | -17.89M | -21.50M | -24.32M |
| EPS Basic | -0.73 | -0.99 | -1.19 | -1.40 | -1.56 |
| Normalized Basic EPS | -0.43 | -0.47 | -0.59 | -0.72 | -0.84 |
| EPS Diluted | -0.73 | -0.99 | -1.19 | -1.40 | -1.57 |
| Normalized Diluted EPS | -0.43 | -0.47 | -0.59 | -0.72 | -0.84 |
| Average Basic Shares Outstanding | 82.04M | 78.15M | 75.47M | 74.51M | 74.30M |
| Average Diluted Shares Outstanding | 82.04M | 78.15M | 75.47M | 74.51M | 74.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |